Three thousand people are expected to attend the four-day meeting in Chicago. Kali Cyrus, an assistant professor at Johns Hopkins who identifies as Black, female and queer, is leading a session tomorrow on bias.
Three thousand pharmacists and other professionals are scheduled to attend the four-day Academy of Managed Care Pharmacy's AMCP 2022 meetiing, which starts tomorrow in Chicago. AMCP officials said that is about a 1,000 more than the attendance at the association’s AMCP Nexus meeting in Denver in October 2021.
The assoication is requiring vaccination but masks are optional.
Suneel Gupta, the author of Backable: The Surprising Truth Behind What Makes People Take a Chance on You and the founding CEO o Rise, a telemedicine start-up, is delivery the keynote on Wednesday.
AMCP officials said one newest addition to this year’s is a session tomorrow titled A Primer on Bias from Discovery to Implementing Strategies to Address. The session is being led by Kali Cyrus, M.D., M.P.H., a psychiatrist and an assistant professor at Johns Hopkins, who offers consulting services on resolving conflicts arising identify differences. Cyrus is a also founder of TIME’s UP Healthcare and a board of the committee to Protect Medicine.
The meeting has education sessions on a variety of topics, ranging sickle cell disease to digital therapeutics to nanomedicine to data analysis to identify racial and ethnic differences. There are also sponsored satellite sessions on a number of diseases, including atopic dermatitis, vulvovaginal candidiasis, diabetes, nonsmall cell lung cancer, and relapsed/refractory myeloma.
The meeting also features research findings, presented as abstracts during poster sessions. The research is ranked on originality, quality, clarity and other factors by 49 reviewers and four editors at the Journal of Managed Care The abstracts were ranked at the top, platinum level. The research topics of those four abstracts are patient and provider preferences for diabetic medications, machine learning in a claims database to characterize patients with heart failure at high risk for wild-type transthyretin amyloid cardiomyopathy, the impact of formulary coverage of Entresto, and the impact of medication therapy management in a pilot project conducted among people covered by Tennessee’s Medicaid program.